کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2167283 | 1092323 | 2011 | 7 صفحه PDF | دانلود رایگان |
In myasthenia gravis (MG), the neuromuscular transmission is impaired by antibodies (Abs) specific for muscle acetylcholine receptor (AChR). Anti-AChR Abs can be detected in the serum of MG patients, although their levels do not correlate with disease severity. In this study, we developed a flow cytometric assay for the detection of peripheral blood AChR-specific B cells to characterize B cell phenotypes associated with experimental autoimmune myasthenia gravis (EAMG). Alexa-conjugated AChR was used as a probe for AChR-specific B cells (B220+Ig+). Mice with EAMG had significantly elevated frequencies of AChR-specific IgG2+ and IgM+ B cells. While the frequencies of IgG2+ B cells and plasma anti-AChR IgG2 levels significantly correlated with the clinical grades of EAMG, the frequencies of IgM+ B cells and plasma anti-AChR IgM levels did not. These results indicate that the frequency of AChR-specific and IgG1+ (mouse IgG2 equivalent) peripheral blood B cells and anti-AChR IgG1 levels could be potential biomarkers for MG disease severity.
► Mice with EAMG have significantly elevated frequencies of AChR-specific IgG2+ and IgM+ B cells.
► Plasma anti-AChR IgG2 levels significantly correlate with the clinical severity of EAMG.
► In human anti-AChR IgG1 could be a potential biomarker for MG disease severity.
► The frequency of AChR-specific B cells could be a potential biomarker for MG disease severity.
Journal: Cellular Immunology - Volume 271, Issue 2, 2011, Pages 292–298